Acute Porphyria Drug Database

J07BH01 - Rota Virus, Live Attenuated
Propably not porphyrinogenic
PNP

Side effects
Fever, diarrhea and vomiting are reported as very common side effects.
Rationale
Based on the pharmacokinetics of the rotavirus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live attenuated human rotavirus RIX4414 strain.
Therapeutic characteristics
The rotavirus vaccine is indicated for the active immunization of infants aged 6 to 24 weeks for prevention of gastro-enteritis due to rotavirus infection. It is administered orally by a 2-dose regimen with an interval of at least 4 weeks. The first dose may be given from the age of 6 weeks must be completed by the age of 24 weeks (preferably before 16 weeks ).
Metabolism and pharmacokinetics
The rotavirus vaccine is not metabolized by the Cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Rotarix. (Last edition: 14.01. 2016). #1881

Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BH or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙